���Ҵ�ý�ƽ������

Vu, an assistant professor in the Department of Computer Science, is improving human cognitive functions using an ear-worn device. To bring the technology to customers worldwide later in 2020, he founded Earable Inc., which now has more than 15 employees.

Randolph, a professor in the Department of Chemical and Biological Engineering, founded VitriVax, a ���Ҵ�ý�ƽ������ spinout, to commercialize new applications of atomic layer deposition techniques for producing thermally stable vaccines.

Funding will support the ongoing development of a nascent RNA drug screen.

Six Boulder-based startups with ties to ���Ҵ�ý�ƽ������ were recognized for their innovation with $1.5 million in grants from the Colorado Office of Economic Development and International Trade.

The companies—Artimus Robotics, Bioloomics, Earable, Emergy, Longpath Technologies, and New Iridium—represent several departments across campus.

Led by its current investors Maverick Ventures and Global Frontier Investments, the funding will be used to advance the development of ColdQuanta’s cold atom Quantum Core technology, the foundation for the company’s development of quantum computers.

A 2-year, $2 million National Cancer Institute (NCI) award has been given to Boulder-based startup SuviCa, Inc. co-founded by ���Ҵ�ý�ƽ������ and CU Cancer Center investigator, Dr. Tin Tin Su. Dr. Su hopes to find drugs that augment the effect of radiation to keep cancer at bay.

The Onyx™ platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow.

A low-cost, high-performance battery chemistry developed by ���Ҵ�ý�ƽ������ researchers could one day lead to scalable grid-level storage for wind and solar energy that could help electrical utilities reduce their dependency on fossil fuels. Venture Partners helped to file the patent on the innovation.

Inscripta gave its first public presentation at the 2019 Synthetic Biology: Engineering, Evolution & Design (SEED) conference in New York City, where the company offered a peek into their progress toward making “the world’s first scalable platform for benchtop digital genome engineering.”